UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Deciding between broad market and sector funds depends on diversification needs and risk tolerance. This guide compares outcomes and helps you decide.
28,547 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Vitalik Buterin is pushing a new DeFi risk model that could soften automatic liquidations by using synthetic, index-l...
Bitcoin edges higher after a late June dip, signaling tentative stabilization as on-chain metrics improve and traders...
Bitcoin slips under $72,000 as on-chain metrics hint a change in market dynamics, with supply normalizing and demand ...
Kris Zacuto has joined Christie’s International Real Estate Southern California as director of luxury estates, bringi...
Brokers are turning to AI-enabled property management as market forces slow home sales, embracing recurring revenue t...
Capri Holdings saw a notable insider purchase when the CEO bought 55,000 shares. This article breaks down what it cou...
June data show existing home sales beat forecasts, signaling ongoing demand strength in 2026. The numbers point to st...
Cardano’s Hoskinson reignites a long-running clash with Ethereum as investors weigh a fresh UTXO-style proposal. ETH ...
A bold market prediction centers on Nvidia stock rising 150% by 2028—but only if a single, enduring driver keeps AI s...
The cybersecurity talent gap is widening as AI skills grow faster than supply. A new market study shows hiring more s...
Ripple’s top executives discussed shutting down the firm after the SEC sued in 2020, a step that would have redirecte...